Old Web
English
Sign In
Acemap
>
authorDetail
>
Aby Buchbinder
Aby Buchbinder
Novartis
Nilotinib
Medicine
Philadelphia Chromosome Positive
Immunology
Imatinib
4
Papers
27
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Pharmacokinetics of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia or acute lymphoblastic leukemia
2019
Clinical Cancer Research
Nobuko Hijiya
C. Michel Zwaan
Carmelo Rizzari
Robin Foà
Floor C.H. Abbink
Donna Lancaster
Judith Landman-Parker
Frédéric Millot
John Moppett
Brigitte Nelken
Maria Caterina Putti
Xianbin Tian
Karen Sinclair
Helene Santanastasio
Aby Buchbinder
Pamela R. Kearns
Show All
Source
Cite
Save
Citations (6)
Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor
2018
The Journal of Clinical Pharmacology
Xianbin Tian
Hefei Zhang
Tycho Heimbach
Handan He
Aby Buchbinder
Mary Aghoghovbia
Florence Hourcade-Potelleret
Show All
Source
Cite
Save
Citations (21)
Early Molecular Response (EMR) with Frontline Treatment Is a Significant Predictor of Long-Term BCR-ABL Transcript Levels in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML) in Chronic Phase
2015
Blood
Giuseppe Saglio
Sonya J. Snedecor
Xiang Ji
Ming-Hui Tai
David Ray
Estella Mendelson
Aby Buchbinder
Pascal Edrich
François-Xavier Mahon
Show All
Source
Cite
Save
Citations (0)
Increased Eligibility for Attempting Treatment-Free Remission (TFR) with Frontline Nilotinib (NIL) vs Imatinib (IM) in Patients with Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia (CML): Results of a Stochastic Simulation Model
2015
Blood
François-Xavier Mahon
An Tran-Duy
Raechelle G. Ocampo
David Ray
Estella Mendelson
Aby Buchbinder
Pascal Edrich
Sonya J. Snedecor
Giuseppe Saglio
Show All
Source
Cite
Save
Citations (0)
1